Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

NCT07011797 · View on ClinicalTrials.gov ↗

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG CX11

Study Locations (17)

Florida

  • Angels Clinical Research Institute - Miami — Doral
  • AES - DRS - Optimal Research Florida - Melbourne — Melbourne
  • Angels Clinical Research Institute — Miami
  • Palm Springs Community Health Center — Miami Lakes
  • Oceanic Research Group, LLC — North Miami Beach

Texas

  • Velocity Clinical Research - Dallas - PPDS — Dallas
  • Epic Clinical Research - Alliance Clinical - Lewisville — Lewisville
  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio — San Antonio
  • Flourish Research - San Antonio - PPDS — San Antonio

California

  • 310 Clinical Research - Alliance Clinical - Los Angeles — Inglewood
  • Acclaim Clinical Research - Alliance Clinical - San Diego — San Diego

Georgia

  • Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS — Savannah
  • Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS — Thomasville

Arizona

  • AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central — Phoenix

Indiana

  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS — Valparaiso

Minnesota

  • Mankato Clinic - East Main Street - Javara - PPDS — Mankato

Ohio

  • Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS — Cincinnati

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-06-17
Est. Completion 2026-04-06
Phase Phase 2

Sponsor

Corxel Pharmaceuticals

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07011797

The ClinicalTrials.gov registry entry for NCT07011797 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corxel Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07011797 reports 17 study locations spanning 8 distinct geographic areas — top geographies include Florida, Texas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07011797 about?

NCT07011797 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants". This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit t...

What is the current status of trial NCT07011797?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-06-17. Estimated completion is 2026-04-06.

What conditions does trial NCT07011797 study?

This clinical trial studies the following conditions: Obesity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07011797?

The interventions under investigation include: Placebo (OTHER), CX11 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07011797?

This trial is sponsored by Corxel Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07011797 being conducted?

This trial has 17 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial